These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

619 related items for PubMed ID: 27104951

  • 1. Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
    Ng TM, Khong WX, Harris PN, De PP, Chow A, Tambyah PA, Lye DC.
    PLoS One; 2016; 11(4):e0153696. PubMed ID: 27104951
    [Abstract] [Full Text] [Related]

  • 2. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.
    Tamma PD, Han JH, Rock C, Harris AD, Lautenbach E, Hsu AJ, Avdic E, Cosgrove SE, Antibacterial Resistance Leadership Group.
    Clin Infect Dis; 2015 May 01; 60(9):1319-25. PubMed ID: 25586681
    [Abstract] [Full Text] [Related]

  • 3. Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
    Ofer-Friedman H, Shefler C, Sharma S, Tirosh A, Tal-Jasper R, Kandipalli D, Sharma S, Bathina P, Kaplansky T, Maskit M, Azouri T, Lazarovitch T, Zaidenstein R, Kaye KS, Marchaim D.
    Infect Control Hosp Epidemiol; 2015 Aug 01; 36(8):981-5. PubMed ID: 25990361
    [Abstract] [Full Text] [Related]

  • 4. Outcomes of treating AmpC-producing Enterobacterales bacteraemia with carbapenems vs. non-carbapenems.
    Tan SH, Ng TM, Chew KL, Yong J, Wu JE, Yap MY, Heng ST, Ng WHW, Wan S, Cheok SJH, Tambyah PA, Lye DC.
    Int J Antimicrob Agents; 2020 Feb 01; 55(2):105860. PubMed ID: 31841674
    [Abstract] [Full Text] [Related]

  • 5. Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis.
    Tsai HY, Chen YH, Tang HJ, Huang CC, Liao CH, Chu FY, Chuang YC, Sheng WH, Ko WC, Hsueh PR.
    Diagn Microbiol Infect Dis; 2014 Nov 01; 80(3):222-6. PubMed ID: 25139843
    [Abstract] [Full Text] [Related]

  • 6. Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study.
    Ko JH, Lee NR, Joo EJ, Moon SY, Choi JK, Park DA, Peck KR.
    Eur J Clin Microbiol Infect Dis; 2018 Feb 01; 37(2):305-311. PubMed ID: 29177611
    [Abstract] [Full Text] [Related]

  • 7. Carbapenem versus Cefepime or Piperacillin-Tazobactam for Empiric Treatment of Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing Escherichia coli in Patients with Hematologic Malignancy.
    Benanti GE, Brown ART, Shigle TL, Tarrand JJ, Bhatti MM, McDaneld PM, Shelburne SA, Aitken SL.
    Antimicrob Agents Chemother; 2019 Feb 01; 63(2):. PubMed ID: 30509935
    [Abstract] [Full Text] [Related]

  • 8. Proposed breakpoint of piperacillin/tazobactam against extended spectrum β-lactamases producing bacteria in bacteremia.
    Sugimoto N, Yamagishi Y, Mikamo H.
    J Infect Chemother; 2017 Jan 01; 23(1):65-67. PubMed ID: 27693013
    [Abstract] [Full Text] [Related]

  • 9. Role of piperacillin/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli.
    Yoon YK, Kim JH, Sohn JW, Yang KS, Kim MJ.
    Int J Antimicrob Agents; 2017 Apr 01; 49(4):410-415. PubMed ID: 28263710
    [Abstract] [Full Text] [Related]

  • 10. Non-intravenous carbapenem-sparing antibiotics for definitive treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamase (ESBL) or AmpC β-lactamase: A propensity score study.
    Meije Y, Pigrau C, Fernández-Hidalgo N, Clemente M, Ortega L, Sanz X, Loureiro-Amigo J, Sierra M, Ayestarán A, Morales-Cartagena A, Ribera A, Duarte A, Abelenda G, Rodríguez-Baño J, Martínez-Montauti J.
    Int J Antimicrob Agents; 2019 Aug 01; 54(2):189-196. PubMed ID: 31075401
    [Abstract] [Full Text] [Related]

  • 11. The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections.
    Tamma PD, Rodriguez-Bano J.
    Clin Infect Dis; 2017 Apr 01; 64(7):972-980. PubMed ID: 28362938
    [Abstract] [Full Text] [Related]

  • 12. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
    Harris PNA, Tambyah PA, Lye DC, Mo Y, Lee TH, Yilmaz M, Alenazi TH, Arabi Y, Falcone M, Bassetti M, Righi E, Rogers BA, Kanj S, Bhally H, Iredell J, Mendelson M, Boyles TH, Looke D, Miyakis S, Walls G, Al Khamis M, Zikri A, Crowe A, Ingram P, Daneman N, Griffin P, Athan E, Lorenc P, Baker P, Roberts L, Beatson SA, Peleg AY, Harris-Brown T, Paterson DL, MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN).
    JAMA; 2018 Sep 11; 320(10):984-994. PubMed ID: 30208454
    [Abstract] [Full Text] [Related]

  • 13. β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts.
    Rodríguez-Baño J, Navarro MD, Retamar P, Picón E, Pascual Á, Extended-Spectrum Beta-Lactamases–Red Española de Investigación en Patología Infecciosa/Grupo de Estudio de Infección Hospitalaria Group.
    Clin Infect Dis; 2012 Jan 15; 54(2):167-74. PubMed ID: 22057701
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of therapy with β-lactam/β-lactamase inhibitor combinations or carbapenems for bacteraemia of nonurinary source caused by ESBL-producing Escherichia coli or Klebsiella pneumoniae.
    Luo H, Xiao Y, Hang Y, Chen Y, Zhu H, Fang X, Cao X, Zou S, Hu X, Xiong J, Zhong Q, Hu L.
    Ann Clin Microbiol Antimicrob; 2021 Sep 06; 20(1):63. PubMed ID: 34488786
    [Abstract] [Full Text] [Related]

  • 17. Non-carbapenem therapy of urinary tract infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae.
    de La Blanchardière A, Dargère S, Guérin F, Daurel C, Saint-Lorant G, Verdon R, Cattoir V.
    Med Mal Infect; 2015 May 06; 45(5):169-72. PubMed ID: 25845927
    [Abstract] [Full Text] [Related]

  • 18. Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam.
    Peterson LR.
    Clin Microbiol Infect; 2008 Jan 06; 14 Suppl 1():181-4. PubMed ID: 18154544
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.